Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunosuppression in Melanoma Immunotherapy: Potential Opportunities for Intervention
Gregory Lizée, Laszlo Radvanyi, Willem W. Overwijk, et al.
Clinical Cancer Research (2006) Vol. 12, Iss. 7, pp. 2359s-2365s
Closed Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
Ryosuke Hino, Kenji Kabashima, Yu Kato, et al.
Cancer (2010) Vol. 116, Iss. 7, pp. 1757-1766
Open Access | Times Cited: 640
Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
Jahan S. Khalili, Shujuan Liu, Tania Rodríguez-Cruz, et al.
Clinical Cancer Research (2012) Vol. 18, Iss. 19, pp. 5329-5340
Open Access | Times Cited: 288
Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden
Pauline Raaschou, Julia F. Simard, Marie Holmqvist, et al.
BMJ (2013) Vol. 346, Iss. apr08 1, pp. f1939-f1939
Open Access | Times Cited: 196
Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma
Tessa Gargett, M. Nazim Abbas, Paul Rolan, et al.
Cancer Immunology Immunotherapy (2018) Vol. 67, Iss. 9, pp. 1461-1472
Open Access | Times Cited: 96
Cancer immunotherapy
Constantin N. Baxevanis, Sonia A. Perez, Michael Papamichail
Critical Reviews in Clinical Laboratory Sciences (2009) Vol. 46, Iss. 4, pp. 167-189
Closed Access | Times Cited: 128
Toll-like Receptors in Tumor Immunotherapy
Chrystal M. Paulos, Andrew Kaiser, Claudia Wrzesinski, et al.
Clinical Cancer Research (2007) Vol. 13, Iss. 18, pp. 5280-5289
Open Access | Times Cited: 121
Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours
Ming Wei, K.A.O. Ellem, Paul Dunn, et al.
European Journal of Cancer (2006) Vol. 43, Iss. 3, pp. 490-496
Closed Access | Times Cited: 105
Microenvironmental influences in melanoma progression
John Tayu Lee, Meenhard Herlyn
Journal of Cellular Biochemistry (2006) Vol. 101, Iss. 4, pp. 862-872
Closed Access | Times Cited: 89
Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial
Antoni Ribas, Jeffrey S. Weber, Bartosz Chmielowski, et al.
Clinical Cancer Research (2011) Vol. 17, Iss. 9, pp. 2987-2996
Open Access | Times Cited: 70
Improving T cell responses to modified peptides in tumor vaccines
Jonathan D. Buhrman, Jill E. Slansky
Immunologic Research (2012) Vol. 55, Iss. 1-3, pp. 34-47
Open Access | Times Cited: 52
Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy
Richard W. Joseph, Vijay R. Peddareddigari, Ping Liu, et al.
Clinical Cancer Research (2011) Vol. 17, Iss. 14, pp. 4882-4891
Open Access | Times Cited: 50
Design of nanosystems for melanoma treatment
Asal Farasatkia, Lidia Maeso, Hamidreza Gharibi, et al.
International Journal of Pharmaceutics (2024), pp. 124701-124701
Open Access | Times Cited: 4
Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy
Gregory Lizée, Mayra A. Cantu, Patrick Hwu
Clinical Cancer Research (2007) Vol. 13, Iss. 18, pp. 5250-5255
Closed Access | Times Cited: 59
Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma
Oliver Goldstein, Laela M. Hajiaghamohseni, Shereen Amria, et al.
Cancer Immunology Immunotherapy (2008) Vol. 57, Iss. 10, pp. 1461-1470
Open Access | Times Cited: 54
Blockade of TGF-β Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer
Gavin Bendle, Carsten Linnemann, Laura Bies, et al.
The Journal of Immunology (2013) Vol. 191, Iss. 6, pp. 3232-3239
Open Access | Times Cited: 42
Smart Lipid-Based Nanosystems for Therapeutic Immune Induction against Cancers: Perspectives and Outlooks
Seth‐Frerich Fobian, Ziyun Cheng, Timo L.M. ten Hagen
Pharmaceutics (2021) Vol. 14, Iss. 1, pp. 26-26
Open Access | Times Cited: 26
Toward Effective Immunotherapy for the Treatment of Malignant Brain Tumors
Duane A. Mitchell, John H. Sampson
Neurotherapeutics (2009) Vol. 6, Iss. 3, pp. 527-538
Open Access | Times Cited: 40
IL-2 and IL-15 Each Mediate De Novo Induction of FOXP3 Expression in Human Tumor Antigen-specific CD8 T Cells
Mojgan Ahmadzadeh, Paul A. Antony, Steven A. Rosenberg
Journal of Immunotherapy (2007) Vol. 30, Iss. 3, pp. 294-302
Open Access | Times Cited: 42
Tumour‐mediated disruption of dendritic cell function: Inhibiting the MEK1/2‐p44/42 axis restores IL‐12 production and Th1‐generation
Andrew M. Jackson, Lori A Mulcahy, Xing Zhu, et al.
International Journal of Cancer (2008) Vol. 123, Iss. 3, pp. 623-632
Open Access | Times Cited: 39
Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma
Esteban Celis
Cancer (2007) Vol. 110, Iss. 1, pp. 203-214
Open Access | Times Cited: 36
Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports
Michele Hooper, Deborah Wenkert, Bojena Bitman, et al.
Pediatric Rheumatology (2013) Vol. 11, Iss. 1
Open Access | Times Cited: 26
Macrophage polarization contributes to the efficacy of an oncolytic HSV-1 targeting human uveal melanoma in a murine xenograft model
Sisi Liu, Junwen Zhang, Sheng Fang, et al.
Experimental Eye Research (2020) Vol. 202, pp. 108285-108285
Closed Access | Times Cited: 19
Serum Autoantibody Profiling Using a Natural Glycoprotein Microarray for the Prognosis of Early Melanoma
Yashu Liu, Jintang He, Xaiolei Xie, et al.
Journal of Proteome Research (2010) Vol. 9, Iss. 11, pp. 6044-6051
Open Access | Times Cited: 25
Human uveal melanoma cells inhibit the immunostimulatory function of dendritic cells
Juan Ma, Yoshihiko Usui, Masaru Takeuchi, et al.
Experimental Eye Research (2010) Vol. 91, Iss. 4, pp. 491-499
Closed Access | Times Cited: 22
An Update on Malignant Melanoma Vaccine Research
Stephen J. Ralph
American Journal of Clinical Dermatology (2007) Vol. 8, Iss. 3, pp. 123-141
Closed Access | Times Cited: 21
Page 1 - Next Page

Scroll to top